These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9786315)

  • 1. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
    Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
    J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
    Rothenberg ML; Eckardt JR; Kuhn JG; Burris HA; Nelson J; Hilsenbeck SG; Rodriguez GI; Thurman AM; Smith LS; Eckhardt SG; Weiss GR; Elfring GL; Rinaldi DA; Schaaf LJ; Von Hoff DD
    J Clin Oncol; 1996 Apr; 14(4):1128-35. PubMed ID: 8648367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
    Goldberg RM; Erlichman C
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on European adjuvant trials with irinotecan for colorectal cancer.
    Douillard JY; Barbarot V; Bennouna J
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
    Berg D
    Oncol Nurs Forum; 1998 Apr; 25(3):535-43. PubMed ID: 9568608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan in the treatment of colorectal cancer.
    Fuchs C; Mitchell EP; Hoff PM
    Cancer Treat Rev; 2006 Nov; 32(7):491-503. PubMed ID: 16959432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
    Khayat D; Gil-Delgado M; Antoine EC; Nizri D; Bastian G
    Oncology (Williston Park); 2001 Apr; 15(4):415-29; discussion 429-30, 433-4. PubMed ID: 11346931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
    Méndez M; Salut A; García-Girón C; Navalon M; Diz P; García López MJ; España P; de la Torre A; Martínez del Prado P; Duarte I; Pujol E; Arizcun A; Cruz JJ
    Clin Colorectal Cancer; 2003 Nov; 3(3):174-9. PubMed ID: 14706177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.
    Fírvida JL; Irigoyen A; Vázquez-Estévez S; Díz P; Constenla M; Casal-Rubio J; Valladares-Ayerbes M; Castellanos J; Rodríguez R; Balcells M
    Cancer; 2001 Feb; 91(4):704-11. PubMed ID: 11241237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
    Shimada Y; Rougier P; Pitot H
    Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
    García-Girón C; García Palomo A; Alonso López C; León Carbonero A; Méndez Ureña M; Adróver Cebrián E; Barceló Galíndez R; Arroyo Yustos M; Alvarez Gallego J
    Clin Transl Oncol; 2005 Jul; 7(6):244-9. PubMed ID: 16131447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.